scholarly journals Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline Summary

2019 ◽  
Vol 15 (7) ◽  
pp. 391-393 ◽  
Author(s):  
Christopher Lieu ◽  
Erin B. Kennedy ◽  
Nancy Baxter
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Adjuvant Therapy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Stage Iii ◽  
Stage Iii Colon Cancer

Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14540-e14540 ◽  
Author(s):  
Valerie Heong ◽  
Michael Jefford ◽  
Hui-Li Wong ◽  
Joseph James McKendrick ◽  
Jayesh Desai ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Adjuvant Therapy ◽  
Routine Clinical Practice ◽  
Stage Iii ◽  
Stage Iii Colon Cancer

Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14608-e14608
Author(s):  
Valerie Heong ◽  
Hui-Li Wong ◽  
Jeanne Tie ◽  
Michael Jefford ◽  
Kathryn Maree Field ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Therapy ◽  
Age Groups ◽  
Routine Clinical Practice ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
N2 Disease ◽  
Co Morbidity

e14608 Background: Adjuvant chemotherapy is a standard of care for patients (pts) with stage III colon cancer. While many retrospective series have concluded that treatment is underutilised in routine clinical practice, particularly in older pts, reasons for this remain unexplored. Methods: Data was collected on all pts with stage III colon cancer attending four community hospitals in Australia between January 2003 and July 2012. Every patient was referred to a medical oncologist. For each case where adjuvant therapy was not delivered, reason(s) were prospectively documented by clinicians in a consensus database. Results: Data was collected on 875 pts. Median age 67 years (range 15 - 92). Overall, 147 (25.9%) did not receive adjuvant therapy. Comorbidity was the main reason for non-treatment in all age groups. Age alone was the reason for not recommending treatment in a small number of elderly pts (n=20, 20.4%). Risk of recurrence (N1 vs N2 disease) did not impact recommendations of clinicians (75% vs 76%) or pt acceptance (92% vs 93%). Pts with a lower socioeconomic status were less likely to be offered treatment; however this reflected greater comorbidity in these pts. Treatment acceptance was similar across all socioeconomic groups (data not shown). Conclusions: In routine clinical practice adjuvant chemotherapy should be recommended to, and can be safely delivered to a very high proportion of younger patients. Clinicians are comfortable recommending adjuvant chemotherapy to older pts, with co-morbidity the dominant reason that treatment was not recommended for pts >65 years. The rate of pts declining treatment increased with age, and further study of the factors involved in treatment refusal should be pursued [Table: see text]

Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients

Medical Care ◽  
2009 ◽  
Vol 47 (12) ◽  
pp. 1229-1236 ◽  
Author(s):  
Amy J. Davidoff ◽  
Thomas Rapp ◽  
Ebere Onukwugha ◽  
Ilene H. Zuckerman ◽  
Nader Hanna ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Stage Iii ◽  
Stage Iii Colon Cancer

scholarly journals Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology

2021 ◽  
Vol 10 (1) ◽  
pp. e000934
Author(s):  
Arielle Elkrief ◽  
Genevieve Redstone ◽  
Luca Petruccelli ◽  
Alla'a Ali ◽  
Doneal Thomas ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Adjuvant Chemotherapy ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cox Regression ◽  
Health Centre ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Mcgill University

PurposeAdjuvant chemotherapy within 56 or 84 days following curative resection is globally accepted as the standard of care for stage III colon cancer as it has been associated with improved overall survival. Initiation of adjuvant chemotherapy within this time frame is therefore recommended by clinical practice guidelines, including the European Society for Medical Oncology. The objective of this study was to evaluate adherence to these clinical practice guidelines for patients with stage III colon cancer across the Rossy Cancer Network (RCN); a partnership of McGill University’s Faculty of Medicine, McGill University Health Centre, Jewish General Hospital and St Mary’s Hospital Center.Patients and methods187 patients who had been diagnosed with stage III colon cancer and received adjuvant chemotherapy within the RCN partner hospitals from 2012 to 2015 were included. Patient and treatment information was retrospectively determined by chart review. Χ2 and Wilcoxon rank-sum tests were used to measure associations and a multivariate Cox regression model was used to determine risk factors contributing to delays in administration of adjuvant chemotherapy.ResultsThe median turnaround time between surgery and adjuvant chemotherapy was 69 days. Importantly, only 27% of patients met the 56-day target, and 71% met the 84-day target. Increasing age, having more than one surgical complication and being diagnosed between 2013–2014 and 2014–2015 reduced the likelihood that patients met these targets. Furthermore, delays were observed at most intervals from surgery to first adjuvant chemotherapy treatment.ConclusionOur study found that within these academic hospital settings, 27% of patients met the 56-day target, and 71% met the 84-day target. Delays were associated with hospital, surgeon and patient-related factors. Initiatives in quality improvement are needed in order to improve adherence to recommended treatment guidelines for prompt administration of adjuvant chemotherapy for stage III colon cancer.

Sign in / Sign up

Export Citation Format

Share Document